Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thorough QT/QTc study of GLPG3667 versus placebo and active comparator in healthy subjects
NL-OMON61163Phase 1Not yet recruiting
- Sponsor
- Galapagos NV
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of GLPG3667 (3 arms), sponsored by Galapagos NV. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
GLPG3667
Beyond the preview
Go deeper on NL-OMON61163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61163.